|

BMI-Driven Tolerability and Efficacy of Entresto in Heart Failure Patients

RECRUITINGSponsored by Lithuanian University of Health Sciences
Actively Recruiting
SponsorLithuanian University of Health Sciences
Started2023-08-10
Est. completion2024-11-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06439069

Summary

This study aims to determine if patients with higher BMI can tolerate higher doses of Entresto (sacubitril/valsartan) and experience better symptomatic and functional outcomes compared to patients with lower BMI.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Adults aged 18 and older
* Diagnosed with heart failure with reduced ejection fraction (HFrEF) (LVEF ≤ 35%)
* Naïve to Entresto therapy or willing to switch from previous ACE inhibitor/ARB therapy
* Ability to provide informed consent

Exclusion Criteria:

* Severe renal or hepatic impairment (e.g., eGFR \< 30 mL/min/1.73m², severe liver disease)
* History of angioedema
* Pregnant or breastfeeding women
* Patients with malignancies or other severe comorbid conditions
* Non-compliance with medication regimen

Conditions3

Heart DiseaseHeart FailureObesity

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.